BLIRT S.A., a biotechnology company, focuses on the production of specialty enzymes utilized in nucleic acid purification and sequencing in Poland. More Details
Flawless balance sheet with outstanding track record.
Share Price & News
How has BLIRT's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BLR is more volatile than 90% of Polish stocks over the past 3 months, typically moving +/- 27% a week.
Volatility Over Time: BLR's weekly volatility (27%) has been stable over the past year, but is still higher than 75% of Polish stocks.
7 Day Return
1 Year Return
Return vs Industry: BLR exceeded the Polish Biotechs industry which returned 219.7% over the past year.
Return vs Market: BLR exceeded the Polish Market which returned -5.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is BLIRT's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StEstimating The Intrinsic Value Of BLIRT S.A. (WSE:BLR)
2 months ago | Simply Wall StIs BLIRT S.A.'s (WSE:BLR) Latest Stock Performance A Reflection Of Its Financial Health?
6 months ago | Simply Wall StIf You Had Bought BLIRT (WSE:BLR) Shares A Year Ago You'd Have Made 440%
Is BLIRT undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BLR (PLN16.9) is trading below our estimate of fair value (PLN27.4)
Significantly Below Fair Value: BLR is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BLR is good value based on its PE Ratio (51.3x) compared to the PL Biotechs industry average (95.3x).
PE vs Market: BLR is poor value based on its PE Ratio (51.3x) compared to the Polish market (12.6x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BLR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BLR is overvalued based on its PB Ratio (21.3x) compared to the PL Biotechs industry average (6.1x).
How is BLIRT forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BLIRT has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine whether BLIRT is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- BLIRT competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has BLIRT performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BLR has high quality earnings.
Growing Profit Margin: BLR's current net profit margins (24.1%) are higher than last year (5.7%).
Past Earnings Growth Analysis
Earnings Trend: BLR has become profitable over the past 5 years, growing earnings by 39.4% per year.
Accelerating Growth: BLR's earnings growth over the past year (880.8%) exceeds its 5-year average (39.4% per year).
Earnings vs Industry: BLR earnings growth over the past year (880.8%) exceeded the Biotechs industry 11.2%.
Return on Equity
High ROE: BLR's Return on Equity (41.6%) is considered outstanding.
How is BLIRT's financial position?
Financial Position Analysis
Short Term Liabilities: BLR's short term assets (PLN14.3M) exceed its short term liabilities (PLN3.3M).
Long Term Liabilities: BLR's short term assets (PLN14.3M) exceed its long term liabilities (PLN303.0K).
Debt to Equity History and Analysis
Debt Level: BLR is debt free.
Reducing Debt: BLR has no debt compared to 5 years ago when its debt to equity ratio was 21.8%.
Debt Coverage: BLR has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: BLR has no debt, therefore coverage of interest payments is not a concern.
What is BLIRT current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BLR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BLR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BLR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BLR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BLR's dividend in 3 years as they are not forecast to pay a notable one for the Polish market.
How experienced are the management team and are they aligned to shareholders interests?
Mr. Marian Popinigis has been the Chief Executive Officer at BLIRT S.A. since July 2018. He is President of the Managemement Board at BLIRT S.A. Mr. Popinigis is a Co-Founder of Mercor S.A. and serves as i...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
BLIRT S.A.'s company bio, employee growth, exchange listings and data sources
- Name: BLIRT S.A.
- Ticker: BLR
- Exchange: WSE
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: zł290.621m
- Shares outstanding: 17.20m
- Website: https://www.blirt.eu
Number of Employees
- BLIRT S.A.
- Trzy Lipy 3/1.38
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BLR||WSE (Warsaw Stock Exchange)||Yes||Common Bearer Shares||PL||PLN||Mar 2011|
BLIRT S.A., a biotechnology company, focuses on the production of specialty enzymes utilized in nucleic acid purification and sequencing in Poland. The company offers a suite of services, including the des...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/28 18:10|
|End of Day Share Price||2020/11/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.